Alphaeon
About Alphaeon
Alphaeon Corporation is a privately held company focused on bringing highly innovative products and services to the aesthetics market. ALPHAEON's lead product candidate is DWP-450, a Botulinum toxin Type A for the treatment of glabellar lines.YEAR FOUNDED:
2013
LEADERSHIP:
CEO: Murthy Simhambhatla
FOLLOW ALPHAEON:
Tweets by Alphaeon
6 articles about Alphaeon
-
ALPHAEON Corporation Completes Reorganization to Simplify its Corporate Structure
1/10/2020
ALPHAEON Corporation, announced that it has completed a reorganization to simplify its corporate structure. As a result of this reorganization the company has split into two business units, each of which will retain the same shareholder base that was in place prior to this split off..
-
ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt
5/21/2019
ALPHAEON intends to use the net proceeds from this offering to pay off a majority of its $88 million in third-party debt obligations, which are due in June 2019.
-
ALPHAEON Corporation sells 4 million shares in Evolus Inc.
5/15/2019
ALPHAEON Corporation announced that it has agreed to sell approximately 4.0 million shares of common stock in Evolus, Inc. in an underwritten public offering with Morgan Stanley acting as sole underwriter for the offering.
-
ALPHAEON repays outstanding principal amount under its secured convertible notes due December 23, 2018
12/3/2018
ALPHAEON Corporation announced today that it has repaid the principal amount (approximately $56 million) of its secured convertible note obligations ahead of their December 23, 2018 maturity date.
-
Strathspey Crown To Acquire ShoutMD From Alphaeon
9/12/2017
-
Alphaeon Submits Biologics License Application For DWP-450 Neuromodulator
5/16/2017